Citius Oncology, Inc. Increase (Decrease) in Accrued Liabilities
Citius Oncology, Inc. (CTOR) reported Increase (Decrease) in Accrued Liabilities of $19.98 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-14
- Citius Oncology, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $16.05K.
- Citius Oncology, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $19.54M, a 683.57% increase year-over-year.
- Citius Oncology, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $425.79K, a 93.16% decline year-over-year.
- Citius Oncology, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$4.37M.
- Citius Oncology, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $4.09M.
- Citius Oncology, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$259.07K.
- Citius Oncology, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $349.05K.
- Citius Oncology, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$801.75K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | $19.55M derived: sum of 2 quarters · filed 2026-08-14 | $19.98M 10-Q · filed 2026-08-14 | $15.62M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $19.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $19.96M 10-Q · filed 2026-05-15 | $15.60M derived: sum of 3 quarters · filed 2026-05-15 | $15.34M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $425.79K 10-Q · filed 2026-02-13 | -$3.94M derived: sum of 2 quarters · filed 2026-02-13 | -$4.20M derived: sum of 3 quarters · filed 2026-08-14 | -$1.71M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | -$4.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | -$4.63M derived: sum of 2 quarters · filed 2026-08-14 | -$2.14M derived: sum of 3 quarters · filed 2026-08-14 | $4.09M 10-K · filed 2025-12-23 |
| 2025-06-30 | -$263.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | $2.23M derived: sum of 2 quarters · filed 2026-08-14 | $8.46M 10-Q · filed 2026-08-14 | $8.01M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $2.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $8.72M 10-Q · filed 2026-05-15 | $8.28M derived: sum of 3 quarters · filed 2026-05-15 | $8.27M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $6.23M 10-Q · filed 2026-02-13 | $5.78M derived: sum of 2 quarters · filed 2026-02-13 | $5.78M derived: sum of 3 quarters · filed 2026-02-13 | $5.89M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | -$445.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | -$447.49K derived: sum of 2 quarters · filed 2025-12-23 | -$335.14K derived: sum of 3 quarters · filed 2025-12-23 | -$259.07K 10-K · filed 2025-12-23 |
| 2024-06-30 | -$2.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $109.86K 10-Q · filed 2024-08-09 | $185.93K 10-Q · filed 2025-08-12 | $185.51K derived: sum of 4 quarters · filed 2025-02-14 |
| 2024-03-31 | $112.35K 10-Q · filed 2024-05-20 | -$259.07K 10-Q · filed 2025-05-14 | $188.00K derived: sum of 3 quarters · filed 2025-02-14 | $254.12K derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-12-31 | -$199.16K 10-Q · filed 2025-02-14 | $75.65K derived: sum of 2 quarters · filed 2025-02-14 | $141.77K derived: sum of 3 quarters · filed 2025-02-14 | $349.05K 10-K · filed 2024-04-16 |
| 2023-09-30 | $274.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-20 | $340.92K derived: sum of 2 quarters · filed 2024-08-09 | $356.87K 10-Q · filed 2023-11-20 | -$801.75K 10-K · filed 2024-12-27 |
| 2023-06-30 | $66.12K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $82.06K 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $15.94K 10-Q · filed 2024-05-20 | |||
| 2022-12-31 | $25.99K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |